PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28859644-0	2017	Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.	Sunitinib	64-73	C-reactive protein	Homo sapiens	20-38	
24215209-0	2014	Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.	Sunitinib	123-132	C-reactive protein	Homo sapiens	36-54	
24215209-1	2014	OBJECTIVE: To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.	Sunitinib	163-172	C-reactive protein	Homo sapiens	52-70	
24215209-1	2014	OBJECTIVE: To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.	Sunitinib	163-172	C-reactive protein	Homo sapiens	72-75	
24215209-12	2014	CONCLUSION: Baseline serum CRP level is a strong independent variable linked with RR, PFS and OS in patients with mRCC treated with sunitinib.	Sunitinib	132-141	C-reactive protein	Homo sapiens	27-30	
22671963-0	2012	C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.	Sunitinib	89-98	C-reactive protein	Homo sapiens	0-18	
22671963-1	2012	OBJECTIVES: To investigate the prognostic role of C-reactive protein in patients with advanced renal cell carcinoma treated with sunitinib.	Sunitinib	129-138	C-reactive protein	Homo sapiens	50-68	
22671963-8	2012	CONCLUSIONS: C-reactive protein is an independent prognostic indicator for patients with advanced renal cell carcinoma treated with sunitinib.	Sunitinib	132-141	C-reactive protein	Homo sapiens	13-31	
29570259-11	2019	CONCLUSION: Our study suggests that dynamic changes in CRP can better predict survival in patients with mRCC who are treated with sunitinib.	Sunitinib	130-139	C-reactive protein	Homo sapiens	55-58	
26320436-8	2015	Six month disease control rate (complete response, partial response and stable disease) in response to sunitinib was significantly higher in patients with normal (<=0.5 mg/dl) than elevated baseline CRP (p<0.001).	Sunitinib	103-112	C-reactive protein	Homo sapiens	202-205	
26320436-9	2015	CONCLUSIONS: CRP is a significant independent predictor of PFS for Japanese patients with mCCRCC treated with first-line sunitinib.	Sunitinib	121-130	C-reactive protein	Homo sapiens	13-16	
26320436-10	2015	Pretreatment CRP concentration may be a useful biomarker predicting response to sunitinib treatment.	Sunitinib	80-89	C-reactive protein	Homo sapiens	13-16	
24612599-3	2014	This study aimed to assess the association between initial tumor size, involved organs, pre-treatment C-reactive protein (CRP) levels, and reduction in tumor size in patients with clear cell RCC (CCRCC) treated with sunitinib.	Sunitinib	216-225	C-reactive protein	Homo sapiens	102-120	
24612599-3	2014	This study aimed to assess the association between initial tumor size, involved organs, pre-treatment C-reactive protein (CRP) levels, and reduction in tumor size in patients with clear cell RCC (CCRCC) treated with sunitinib.	Sunitinib	216-225	C-reactive protein	Homo sapiens	122-125	
24612599-11	2014	CONCLUSIONS: Patients with CCRCC with smaller lung metastatic lesions and lower CRP levels may achieve greater percent reductions in tumor size with sunitinib therapy than patients with extra-pulmonary lesions, large lung lesions, and/or higher CRP levels.	Sunitinib	149-158	C-reactive protein	Homo sapiens	80-83	
28859644-13	2017	CONCLUSION: Baseline CRP was a significant predictive factor of sunitinib response and a prognostic factor of survival.	Sunitinib	64-73	C-reactive protein	Homo sapiens	21-24	
28529744-0	2017	Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib.	Sunitinib	101-110	C-reactive protein	Homo sapiens	27-45	
28529744-2	2017	The aim of the present study was to investigate the prognostic effect of pretreatment serum CRP level and CRP kinetics on patients with advanced RCC treated with sunitinib.	Sunitinib	162-171	C-reactive protein	Homo sapiens	106-109	
28529744-2	2017	The aim of the present study was to investigate the prognostic effect of pretreatment serum CRP level and CRP kinetics on patients with advanced RCC treated with sunitinib.	Sunitinib	162-171	C-reactive protein	Homo sapiens	92-95	
28529744-9	2017	Therefore, CRP kinetics and normal pretreatment CRP level are prognostic indicators in patients with advanced RCC treated with sunitinib.	Sunitinib	127-136	C-reactive protein	Homo sapiens	11-14	
28529744-9	2017	Therefore, CRP kinetics and normal pretreatment CRP level are prognostic indicators in patients with advanced RCC treated with sunitinib.	Sunitinib	127-136	C-reactive protein	Homo sapiens	48-51